B Y S O L C O L O N

PHARMA BIG CHALLENGE

The ability to create innovative products

The pharmaceuticalindustry has been  a

big  disruptor and 

has  enjoyed of many years of stability , but if  they  don't innovate soon, they will  be  disrupted

.

.Add a little bit of body text

PwC surveyed 1,757 C-suite and executive-level respondents , across more

than 25 countries and 30 sectors who are responsible for overseeing

innovation within their company . The sample of 76 respondents from the

Pharma sector on 13 countries said that less than 14% of revenues are

coming from new products and services launched in the past years ,compared

to 25% for the top innovators . That's lower than in most other industries.

Managing Innovation

B I G D R I V E R S F O R I N N O V A T I O N R I G H T

N O W

# 1R&D HIGH COST

# 2TECHNOLOGY

# 3ADOPTION OF

NEW BUSINESS MODELS

#4 REGULATORY

POLICY

HIGH COSTS OF R&D

The pharma industry spends about

$140 billion a year in R&D .

For this investment we are getting 

25 to 35 new drugs.

Some of  them are profitable but

others are too marginal.

TECHNOLOGY

Technology is transforming

medicine,science and research tools.

The digitization of the medicine is

changing  the way  we  practice it.

Massive volume of data generated by

mobile devices and biosensors will soon

give parallel insights  into poor

understood diseases.

These amount of data will  improve the

controlled trials helping to formulate

better hypotheses about what causes

diseases in much less time.

NEW BUSINESS MODEL

The traditional  big  pharma

models carrries high costs  .

Spend  $4 billion to $10 billion  in

R&D per ech drug  they bring to

market.

Small pharma , do  the same thing

for a few hundred million to a couple

of billions, 50%-90% cheaper.

Virtual pharma, networked models

are vying to do it better.

Some big pharma are getting  the

message, leverage networked

innovation,embracing precompetitive

    collaboration.

REGULATORY POLICY

• Policy makers can change things quickly. US

government purchases around &billion worth of

drugs per year.

• Countries like Germany, UK, Canada where

governments are using their power as single payers

to tamp down prices and curtail reimbursements.

• FDA has recently implemented a regulatory

innovation- The Breakthrough Therapy

Designation-and is having an enormous impact in

innovation.

• Regulators understands that regulations must

evolve with science. This is needed for technologies

such as cell therapies, gene therapy, synthetic

biology, biosensors and digital health devices.

INNOVATION IS THE ONLY WAY TO WINSteve Jobs

"If the Pharma industry does not innovate,it will be

disrupted"

"THE ABILITY TO GENERATE IDEAS IS NOT  MERELY A     FUNCTION OF THE  MIND ,  BUT ALSO A FUNCTION OF BEHAVIOURS. IF WE CHANGE OUR   BEHAVIOURS WE CAN IMPROVE   OUR  CREATIVE CAPACITY"                          

"The Innovator's DNA:Mastering the Five Skills of Disruptive

Innovators", Hal Gregersen,Jeffey Dyer,Clayton Christensen

Questioning Five Discovery Skills

Observing

NetworkingExperimentingAssociating

thank you

References:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfmevent=reportSSearch.process

https://www.pwc.com/gx/en/pharma-life-sciences/assets/pwc-managing-innovation-pharma.pdf

https://www.forbes.com/sites/medidata/2014/10/06/the-next-wave-of-pharmaceutical-innovation-an-inter

view-with-bernard-munos/#48622e166651

http://www.claytonchristensen.com/books/innovators-dna-mastering-skills-disruptive-innovators/

Images Credits: https://www.swansonreed.com/wp-content/uploads/2015/05/Science-writing.jpg

https://www.google.com/url

Sol Colon linkedin.com/in/solcolon

https://twitter.com/solcolonrios